Veradermics, Incorporated (MANE) - Total Assets
Based on the latest financial reports, Veradermics, Incorporated (MANE) holds total assets worth $398.58 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Veradermics, Incorporated - Total Assets Trend (2023–2025)
This chart illustrates how Veradermics, Incorporated's total assets have evolved over time, based on quarterly financial data. Also see Veradermics, Incorporated stock valuation for the company's overall valuation and market capitalisation.
Veradermics, Incorporated - Asset Composition Analysis
Current Asset Composition (December 2025)
Veradermics, Incorporated's total assets of $398.58 Million consist of 99.9% current assets and 0.1% non-current assets. Review Veradermics, Incorporated balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 14.3% |
| Accounts Receivable | $1.25 Million | 0.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2023–2025)
This chart illustrates how Veradermics, Incorporated's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Veradermics, Incorporated for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Veradermics, Incorporated's current assets represent 99.9% of total assets in 2025, an increase from 95.2% in 2023.
- Cash Position: Cash and equivalents constituted 14.3% of total assets in 2025, down from 88.3% in 2023.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2023.
- Asset Diversification: The largest asset category is accounts receivable at 0.8% of total assets.
Veradermics, Incorporated Competitors by Total Assets
Key competitors of Veradermics, Incorporated based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Veradermics, Incorporated - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 59.12 | 11.77 | 11.77 |
| Quick Ratio | 59.12 | 11.77 | 11.77 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $390.35 Million | $50.82 Million | $50.82 Million |
Veradermics, Incorporated - Advanced Valuation Insights
This section examines the relationship between Veradermics, Incorporated's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.10 |
| Latest Market Cap to Assets Ratio | 25.84 |
| Asset Growth Rate (YoY) | 157.0% |
| Total Assets | $152.62 Million |
| Market Capitalization | $3.94 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Veradermics, Incorporated's assets at a significant premium (25.84x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Veradermics, Incorporated's assets grew by 157.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Veradermics, Incorporated (2023–2025)
The table below shows the annual total assets of Veradermics, Incorporated from 2023 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $152.62 Million | +157.01% |
| 2024-12-31 | $59.38 Million | +221.75% |
| 2023-12-31 | $18.46 Million | -- |
About Veradermics, Incorporated
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in t… Read more